Gilead Sciences, Inc.
NASDAQ:GILD 4:00:00 PM EDT
| Market Cap (Intraday) | 106.08B |
| Current PE | 102.69 |
| Forward PE | 22.48 |
| 2yr Forward PE | 11.79 |
| 10-Day MA | $84.35 |
| 50-Day MA | $79.03 |
| 200-Day MA | $72.54 |
Gilead Sciences, Inc. Stock, NASDAQ:GILD
333 Lakeside Drive, Foster City, California 94404
United States of America
Phone: +1.650.574.3000
Number of Employees: 18000
Description
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.